<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674855</url>
  </required_header>
  <id_info>
    <org_study_id>DA3031_NP_III</org_study_id>
    <nct_id>NCT01674855</nct_id>
  </id_info>
  <brief_title>Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia</brief_title>
  <acronym>PEG-G-CSF</acronym>
  <official_title>Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily
      G-CSF in chemotherapy-induced neutropenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects are randomly assigned to receive once-per-cycle DA-3031(PEG-G-CSF) or daily
      G-CSF(up to 10 days). This study is conducted for 6 cycles of chemotherapy, that each cycle
      is repeated every 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of grade 4 neutropenia in cycle 1</measure>
    <time_frame>21 day</time_frame>
    <description>Grade 4 neutropenia means the ANC count is less than 500/mm3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ANC nadir in cycle 1</measure>
    <time_frame>21 day</time_frame>
    <description>ANC nadir means the lowest point of ANC count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery in cycle 1</measure>
    <time_frame>21 day</time_frame>
    <description>ANC recovery means the ANC count is more than 2,000/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>126 day</time_frame>
    <description>Febrile neutropenia means the ANC count is less than 1,000/mm3 and body temperature is more than 38.3 degrees celsius.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of IV antibiotics administration</measure>
    <time_frame>126 day</time_frame>
    <description>IV antibiotics administration means that antibiotics are administered through intravenous route.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Chemotherapy Induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>DA-3031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leucostim®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-G-CSF</intervention_name>
    <description>Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle</description>
    <arm_group_label>DA-3031</arm_group_label>
    <other_name>DA-3031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle</description>
    <arm_group_label>Leucostim®</arm_group_label>
    <other_name>Leucostim®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age : ≥18, ≤70

          2. Diagnosis of stage II, III or IV breast cancer

          3. ANC≥1,500/mm3, Platelet≥100,000/mm3, ECOG : 0 or 1

          4. Creatinine &lt; 1.5 x ULN

          5. Total bilirubin/AST/ALT &lt; 1.5 x ULN, ALP &lt; 2.5 x ULN

          6. Have given a written, informed consent

        Exclusion Criteria:

          1. Prior chemotherapy

          2. Prior bone marrow or stem cell transplantation

          3. Other malignancy history within 5 years

          4. Prior exposure to pegfilgrastim or filgrastim or other colony-stimulating factors

          5. Received any other investigational drugs within 30 days of informed consent date

          6. Radiation therapy within 4 weeks of informed consent date

          7. Infective symptom before chemotherapy into this study

          8. Received systemic antibiotics within 72 hours of randomization into this study.

          9. HIV positive

         10. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeHong Seo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University GURO hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PEG-G-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

